Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcome

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Childhood survivors of brain tumors who were diagnosed at age 10 or younger have worse depressive symptomatology and social skills and lower feelings of self-worth than their counterparts who were diagnosed as pre-teens or teenagers

AMELIA ISLAND, Florida—Childhood survivors of brain tumors who were diagnosed at age 10 or younger have worse depressive symptomatology and social skills and lower feelings of self-worth than their counterparts who were diagnosed as pre-teens or teenagers, Fiona S.M. Schulte said at the American Psychosocial Oncology Society Third Annual Conference (abstract P6-2). This finding goes counter to previously held assumptions that younger children are immune from the emotional effects of such a devastating diagnosis, said Ms. Schulte, a PhD student in the Department of Psychology at the Hospital for Sick Children, University of Toronto.

Perception of Self-Worth

Ms. Schulte and her supervisor, Maru E.C. Barrera, MD, evaluated 58 survivors of pediatric brain tumors (aged 8 to 19 years), 7 years, on average, after completion of their treatment. Overall, as the children's perception of their self-worth and personal social skills increased, their depression scores decreased. "This was what you would expect," Ms. Schulte said. However, children who were diagnosed before age 10 had significantly higher depression scores than those diagnosed as preadolescents (age 11 to 13) or adolescents (age 14 to 17). This younger cohort also rated themselves as having lower social skills, compared to the older cohorts.

"Older age at diagnosis and high self-worth may serve as protective factors for perceptions of social skills and depressive symptoms," Ms. Schulte concluded. "These younger children are an important group to target from the beginning with interventions to help them with their social skills and their depression."

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
Related Content